NPRO Napro Biotherapeutics (MM)

NaPro BioTherapeutics Announces the Appointment of Anne Bailey as Vice President and General Manager, Genomics Division BOULDER, Colo., Dec. 22 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc announced today the appointment of Anne Bailey as its Vice President of Diagnostics and Reagents and General Manager of its Genomics Division. Ms. Bailey has over 25 years of management experience in the medical diagnostics, reference laboratory and research products industries. Ms. Bailey received her B.S. in Biology/Chemistry from Samford University and an M.S. in Biochemistry from Johns Hopkins University. Most recently Ms. Bailey served as Vice President of Diagnostics at Variagenics and has held additional management positions at Avitech Diagnostics, Photest Diagnostics and Metpath, Inc. Ms. Bailey commented on her appointment, "I am excited to join NaPro's team of talented scientists at this pivotal time in the company's development. I believe there is a wealth of untapped commercial value for both therapeutic and diagnostic applications for NaPro's gene editing technology. I look forward to participating in the commercialization of this unique platform technology." NaPro also announced that Mr. Jeffrey White, the President of NaPro's Genomics Division, would be leaving the company, effective January 2, 2004, to pursue other opportunities. Mr. White will continue as a consultant to the Company. "We are delighted to have a manager of Anne Bailey's strong background and experience joining us at this time in our Genomics Division," commented Leonard P. Shaykin, Chairman and CEO of NaPro. "At the same time, we are sorry to see Jeff White leave NaPro. He has established a strong foundation for our therapeutic and diagnostic programs within the Genomics Division. We all wish him well in his future endeavors." About NaPro BioTherapeutics NaPro BioTherapeutics, Inc., is a life science company focused on the development of targeted therapies for the treatment of cancer and hereditary disease. Forward Looking Statements The statements in this news release that are not historical facts are forward-looking statements that represent management's beliefs and assumptions as of the date of this news release, based on currently available information. Forward-looking statements can be identified by the use of words such as "believes," "intends," "estimates," "may," "will," "should," "anticipated," "expected" or comparable terminology or by discussions of strategy. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it cannot assure that these expectations will prove to be correct. Such statements involve risks and uncertainties including: risks associated with development of the genomics, gene editing and targeted businesses, including competition from companies in similar businesses, limitations on the ability to market products because of the intellectual property rights of third parties, the ability to obtain, maintain and enforce patents; the costs of continuing development of any or all of the Company's development programs; the timing of when those programs will enter the clinic; the successful commercialization of the Company's platform technologies; the fact that the Company's business will require substantial additional investment that the Company has not secured; and the risk that the Company's cash not be sufficient to fund the Company's strategic plans for the initial development new proprietary therapeutic candidates; and all of those factors identified under the captions "Risk Factors," "Special Note Regarding Forward Looking Statements" or "Cautionary Note Regarding Forward Looking Statements" in the Company's documents filed from time to time with the SEC, including the Company's registration statement on Form S-3, as amended, dated August 8, 2003, its Annual Report on Forms 10-K and 10-K/A for the year ending December 31, 2002 filed with the SEC on March 27, April 30, August 8 and October 24, 2003, and its Quarterly Report on Form 10-Q for the quarter ended July 2, 2003 filed with the Securities and Exchange Commission on August 8, 2003. Should one or more of these risks materialize (or the consequences of such a development worsen), or should the underlying assumptions prove incorrect, actual results could differ materially from those forecasted or expected. The Company disclaims any intention or obligation to update publicly or revise such statements whether as a result of new information, future events or otherwise. DATASOURCE: NaPro BioTherapeutics, Inc. CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro BioTherapeutics, +1-212-218-8715; or Investors, Lilian Stern of Stern Investor Relations, +1-212-362-1200, for NaPro BioTherapeutics; or Media, Peter Steinerman, +1-516-374-3031, for NaPro BioTherapeutics

Copyright